Catalyst Pharma (CPRX) Company Gross Revenue
Catalyst Pharmaceuticals is recruiting leading clinicians to combat rare brain pathologies. The company aims for dominance in the orphan segment through the acquisition of new assets. Sales revenue for the company on GURU.Markets reflects business dynamics where 0.60 serves as the base parameter value. Stability of indicators is ensured through the complete outsourcing of production according to GMP standards.
Comprehensive metric breakdowns and analytics for Catalyst Pharmaceuticals, Inc. (CPRX)
- market price and analyst price targets:
- market capitalization details:
- book capitalization data:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Catalyst Pharmaceuticals|CPRX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Catalyst Pharma|CPRX - Company Aggregate Debts|Debts to Book Capitalization Catalyst Pharmaceuticals, Inc.|CPRX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Catalyst Pharmaceuticals|Quick Liquidity Indicator catalystpharma.com
- earnings and valuation multiples information:
CPRX - Net Profit|Projected Future Earnings Catalyst Pharmaceuticals|CPRX - P/E Multiple|Projected Price to Earnings catalystpharma.com|CPRX - PEG Multiple|Company Value to EBITDA Catalyst Pharmaceuticals, Inc.|CPRX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Catalyst Pharmaceuticals|CPRX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months catalystpharma.com|CPRX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Catalyst Pharmaceuticals
- issuer revenue and sales details:
Summary company analysis:CPRX, Catalyst Corp
Automation of drug synthesis for rare diseases at Catalyst Pharmaceuticals (CPRX) is accelerating development, yet commercial success remains contingent upon passing rigorous clinical trials. By analyzing the company's overall sales, an investor can monitor daily revenue inflows, allowing for the identification of signs of business stagnation or overheating by comparing current income with historical trends to avoid overpaying for a slowing asset.
Analysis of competing companies
Company Total Revenue Biogen Idec BIIB|Company Revenue Neurocrine Biosciences (NBIX)|Company Gross Revenue regencellbioscience.com|Axsome Therapeutics, Inc. - Company Sales|Company Total Sales ACAD (ACADIA Pharma)|XENE: Company Sales|Company Sales Revenue VKTX (Viking Therapeutics Corp)|Supernus Pharmaceuticals (SUPN) - Company Revenue|Company Annual Revenue DNLI (denalitherapeutics.com)|HRMY (Harmony Biosciences Holdings, Inc.) - Revenue and Sales Volume|BHVN: Company Sales Revenue|Revenue and Sales Volume AMLX|Revenue and Sales Volume Trevi Corp (TRVI)|Company Revenue Praxis Precision Medicines PRAX|Company Sales Revenue AVXL|CBLL - Company Revenue|Prothena Corporation plc (PRTA) - Company Sales|ALEC: Revenue and Sales Volume|Annexon Biosciences Inc. (ANNX) - Revenue and Sales Volume|OMER (Omeros Corp) - Revenue and Sales Volume|Company Sales neurogene.com (NGNE)|Revenue and Sales Volume ACIU|VYGR - Company Total Revenue|Neumora Therapeutics Inc - Company Sales|Revenue and Sales Volume Scilex Holding Company, Inc. SCLX|TVGN: Company Sales|Alpha Cognition - Company Total Sales|CGTX: Revenue and Sales Volume|IKT - Company Gross Revenue|SAVA (Cassava) - Revenue and Sales Volume|Company Sales Assertio Therapeutics (ASRT)|Revenue and Sales Volume COYA|Revenue and Sales Volume vistagen.com (VTGN)|Company Revenue Ovid Therapeutics OVID|Acumen Pharmaceuticals Inc. - Company Revenue|CRVO - Company Revenue|Company Gross Revenue Alterity Therapeutics ATHE|CLNN: Revenue and Sales Volume|Company Sales PepGen|Company Revenue Jupiter Neurosciences Inc|Relmada Therapeutics Inc - Company Annual Revenue|Company Revenue Annovis Bio Corp (ANVS)|GRCE (gracetx.com) - Company Sales Revenue|Firefly Neuroscience, Inc - Company Sales|KLTO: Company Sales Volume|NRSN - Company Revenue|RVPH (Reviva Pharmaceuticals Holdings Inc.) - Company Sales Volume|MTVA: Revenue and Sales Volume|Company Total Revenue NeurAxis Inc (NRXS)|Company Sales HSDT|Revenue and Sales Volume Passage Bio Corp|Company Revenue Neuphoria Therapeutics Inc. (NEUP)|NERV (Minerva Neurosciences Inc) - Company Sales Revenue|Company Revenue Athira ATHA|Addex (ADXN) - Company Total Revenue|Alzamend - Revenue and Sales Volume|Cyclerion Therapeutics (CYCN) - Company Sales|PTIX: Revenue and Sales Volume|Pasithea Therapeutics Corp. (KTTA) - Revenue and Sales Volume|Company Sales CRGT|ATXI (Avenue Therapeutics Inc) - Company Total Sales|Revenue and Sales Volume BCLI|Revenue and Sales Volume caratherapeutics.com (CARA)|Company Revenue Chromocell Therapeutics Corp. CHRO|Eliem Therapeutics, Inc. - Company Revenue|ITCI: Company Sales|Company Total Revenue Longboard|Marinus Pharmaceuticals (MRNS) - Company Revenue|NKGN - Company Gross Revenue|Company Sales NRBO|SAGE (Sage Therapeutics Inc.) - Company Total Sales|Company Sales SNPX (Neurotrope)|TRVN (Trevena Inc) - Company Sales Revenue|Company Revenue Vigil Neuroscience, Inc. VIGL|WENA (Anew Medical Inc.) - Company Annual Revenue|Cerevel Therapeutics, Inc. - Revenue and Sales Volume
